In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:Possible synergy between PARP inhibitors and androgen receptor–directed therapyRationale for PARP inhibitors and immunotherapy combinationsBenefits and challenges of combining DNA damaging agents and PARP inhibitorPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineInstitut Gustave RousseyVillejuif, FranceJoaquin Mateo, MD, PhDAttending PhysicianMedical OncologyVall d’Hebron University Hospital,Barcelona, SpainContent is part of an online program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:https://bit.ly/3spLzqa

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related